Omega-3 capsules occupy an odd place on the supplement shelf. They are sold on a nutritional argument most nutrition authorities accept — that the long-chain fats in oily fish matter — while the capsule itself is a highly perishable oil sealed in a soft wrapper and expected to sit in a warm kitchen for a year or more.
Two papers published in the past month look at opposite ends of that promise. One took twelve over-the-counter products apart in a laboratory and measured how far the oil inside had already degraded. The other ran a twelve-week placebo-controlled trial of two grams a day in people already being treated for high blood pressure and high cholesterol. Together they describe a category where the contents vary more than the label implies and the clinical effect is smaller and shakier than the marketing suggests.
What the twelve bottles contained
The laboratory study, published in Foods on 22 October, bought twelve omega-3 supplements from a pharmacy in Poland — eight fish-oil products and four algae-derived ones — and measured the oil against the standard chemical indices of lipid quality: acid value, peroxide value, p-anisidine value and the combined TOTOX index, alongside fatty acid composition by gas chromatography and oxidative stability by calorimetry.
The composition was broadly what the products claimed: fish-oil capsules carried both EPA (17.50% to 38.76%) and DHA (13.42% to 36.83%), while the algal products were mostly DHA (36.83% to 62.79%) with little EPA.
The oxidation markers were a different story. Peroxide values — a measure of the first stage of lipid oxidation — ran from 2.08 to 6.97 meq O₂/kg against a recommended ceiling of 5 used by both the Global Organization for EPA and DHA Omega-3 and Codex Alimentarius; several samples were over it. Secondary oxidation products, measured as p-anisidine value, ranged from 7.46 to 27.03, and three products exceeded the recommended limit of 20. TOTOX, which combines the two, ran from 11.57 to 36.43 against a guideline of 26, and five of the twelve products were above it. Acid values, by contrast, stayed within the Codex threshold in every sample.
Oxidation is not spoilage, and none of this shows any product was unsafe; what it shows is that “omega-3 supplement” describes a range, wide enough to be visible in a dozen bottles from one country. The authors are explicit that twelve products, unevenly split between packaging types and assessed at a single point in their shelf life, cannot stand in for a market. They also flag that a much larger survey of 72 marine and microalgal oils sold in the United States found a high proportion above recommended oxidation limits, with flavoured products faring markedly worse — though flavour compounds can interfere with the assay itself, which makes that comparison a rough one.
Why a sealed capsule can still go off
The chemistry is not mysterious. DHA carries six double bonds and EPA five, and those bonds are exactly what makes the fats useful and what makes them vulnerable to oxygen. The more DHA an oil contains, the faster it can oxidise — which is why the algal products in this study, richest in DHA, generally showed the shortest oxidation induction times (6.73 to 9.35 minutes, against up to 18.71 minutes for the best-performing fish oil).
Formulation mattered more than the source. The most stable product in the study was packed in orange glass, which the authors attribute to a combination of its antioxidant system and the light protection; the least stable of the fish oils carried added vitamin E. Encapsulation, they conclude, does not by itself prevent oxidative deterioration — the antioxidant system, the packaging and the handling before the capsule is sealed all bear on what is left when a consumer opens the bottle.
None of that is printed on a label. A shopper can read the EPA and DHA numbers, the serving size and the expiry date, but not a peroxide value.
The dose half: two grams a day for twelve weeks
The second paper, in Nutrients on 9 November, asked a narrower question: in adults already on medication for hypertension and dyslipidaemia, does adding 2 grams a day of omega-3 ethyl esters change inflammatory markers, blood pressure or vascular measures over twelve weeks?
It was a single-centre trial in Buenos Aires: 139 people screened, 39 excluded, 100 randomised to omega-3 or matching placebo, 46 in each group completing the intervention. Treatment was added to stable usual medication, and blood pressure was measured both in the office and over 24 hours.
Against placebo, several outcomes moved. The neutrophil-to-lymphocyte ratio fell by 0.43 (95% CI −0.73 to −0.13), ferritin by 47.32 ng/mL (−77.55 to −17.08), daytime systolic ambulatory pressure by 6.52 mmHg (−10.66 to −2.39), night-time diastolic pressure by 5.55 mmHg (−9.87 to −1.22), central systolic pressure by 6.71 mmHg (−12.22 to −1.20), and an estimated pulse-wave velocity by 0.77 m/s (−1.19 to −0.36).
Then the results that did not move. Office blood pressure showed no significant group-by-time interaction, and neither did hs-CRP — the distinction the authors lean on to argue this was a selective response rather than a general anti-inflammatory effect. Cardiometabolic biomarkers were unchanged.
Reading those numbers carefully
The trial’s own framing is the most useful part of it. It is labelled exploratory, the p-values are nominal, and the confidence intervals were not adjusted for multiplicity across a long list of outcomes. The authors write that multiplicity, limited sample size and incomplete outcome availability “preclude confirmatory interpretation,” and that replication in larger trials with prospectively specified endpoints is required.
Three details sharpen that caution. The study had no single confirmatory primary endpoint, so the headline finding is whichever nominally significant result a reader picks. Trial registration happened retrospectively, after the study was completed. And at baseline, 73.8% of the placebo group reported being physically active against 48.0% of the omega-3 group — a chance imbalance in a variable with well-established effects on blood pressure. A post hoc adjustment for activity produced broadly similar estimates, but the authors note the data were incomplete and cannot account for changes during follow-up.
The vascular measure deserves its own sentence: the estimated pulse-wave velocity is derived by algorithm from oscillometric readings, not measured directly between the carotid and femoral arteries, and baseline values existed for only 51 participants. The paper says plainly it should not be read as independent evidence of improved arterial stiffness.
So the honest summary is a set of exploratory signals in a small trial, pointing the same direction as earlier work on omega-3 and blood pressure, in a population already taking medication. That is a hypothesis worth testing properly. It is not a reason to add a capsule to a regimen.
What the guidance actually says
Harvard’s Nutrition Source recommends fish or seafood once or twice a week and notes that while fatty fish intake is strongly supported, “many large clinical trials have not shown that taking omega-3 supplements provide the same protection.” It cites the American Heart Association’s advisory, which found a modest reduction in cardiac deaths and judged supplements reasonable for people who already have heart disease, but not supported for prevention.
Its dose figures are worth knowing because they differ from what a bottle may suggest. The FDA specifies that supplement labels should not recommend a daily EPA and DHA intake above 2,000 mg; the AHA suggests 1,000 mg a day for people with existing heart disease, preferably from fish, and 2,000 to 4,000 mg under medical supervision when the goal is lowering triglycerides. Harvard also notes that omega-3 supplements can act as a mild blood thinner and may increase bleeding risk — a reason to tell a clinician rather than self-manage.
Regulation is the other half of the quality question. As the FDA’s own consumer explainer puts it, the agency “does NOT have the authority to approve dietary supplements for safety and effectiveness, or to approve their labeling, before the supplements are sold to the public.” Responsibility for a product being what it claims sits with the firm that sells it.
This is the same arithmetic that turned up in our census of vitamin B6 labels and in our audit of sea moss products: the aisle is not one thing, and the label is a claim rather than a measurement.
What we did not find
No trial that gives people supplements with known oxidation levels and follows health outcomes, so there is no evidence here that a stale capsule harms anyone. No head-to-head outcome trial of fish-derived versus algal omega-3. No dose-response data from this trial, since it tested a single dose. And no independent verification of the twelve products’ labels beyond fatty acid composition — the study measured oils, not marketing claims about where they came from.
What exists is a category with real variability and a clinical evidence base that is modest, conditional, and — in this latest trial — explicitly preliminary. None of this is a reason to stop a supplement a clinician recommended. It is a reason to treat the bottle as a product with a supply chain behind it, and to read the guidance as guidance for populations rather than a promise about one person.
If you take omega-3 for a diagnosed condition, or alongside blood pressure or blood-thinning medication, the sensible step is to raise it with a healthcare professional rather than adjust the dose yourself. Our medical disclaimer explains the limits of what an article like this can tell you.